Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia

Amanda Przespolewski, Aaron D. Goldberg, Chetasi Talati, Salman Fazal, Pankit Vachhani, Srinivasa R. Sanikommu, Swapna Thota, Julian Waksal, Brian Ball, Christopher Famulare, Maximilian Stahl, Jeffrey Baron, Elizabeth A. Griffiths, James E. Thompson, Kendra Sweet, Eunice S. Wang

Blood (2023) 141 (12): 1489–1493.

https://doi.org/10.1182/blood.2022016678

Published: 2023

Includes: Supplemental data

Journal Articles

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R. Wilson, Marina Konopleva, Arthur E. Frankel, Vikas Gupta, Ruben Mesa, Matthew Ulrickson, Edward Gorak, Sumeet Bhatia, Tulin Budak-Alpdogan, James Mason, Maria Teresa Garcia-Romero, Norma Lopez-Santiago, Gabriela Cesarman-Maus, Pankit Vachhani, Sangmin Lee, Vijaya Raj Bhatt, William Blum, Roland B. Walter, Dale Bixby, Ivana Gojo, Madeleine Duvic, Raajit K. Rampal, Marcos de Lima, James Foran, Amir T. Fathi, Aric Cameron Hall, Meagan A. Jacoby, Jeffrey Lancet, Gabriel Mannis, Anthony S. Stein, Alice Mims, David Rizzieri, Rebecca Olin, Alexander Perl, Gary Schiller, Paul Shami, Richard M. Stone, Stephen Strickland, Matthew J. Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Monica Guzman, Gail J. Roboz, Joseph Khoury, Muzaffar Qazilbash, Phyu P. Aung, Branko Cuglievan, Yazan Madanat, Mohamed A. Kharfan-Dabaja, Anna Pawlowska, Justin Taylor, Martin Tallman, Prajwal Dhakal, Andrew A. Lane

Blood (2023) 141 (6): 567–578.

https://doi.org/10.1182/blood.2022017865

Published: 2023

Journal Articles

Impact of Therapy on the Anamnestic Response to Seasonal Influenza Vaccination in Patients with Myeloid Malignancies

Kyle R Wiatrowski, Pragya Srivastava, Alan Hutson, Hana Golding, Surender Khurana, Lisa King, Jody Manischewitz, Molly Sheehan, Pankit Vachhani, Amanda Przespolewski, James E. Thompson, Eunice S. Wang, Michael J Nemeth, Elizabeth A. Griffiths

Blood (2022) 140 (Supplement 1): 315–316.

https://doi.org/10.1182/blood-2022-162720

Published: 2022

Journal Articles

Optimal Induction and Consolidation Strategy for Patients with Complex Karyotype and TP53 -Mutated Acute Myeloid Leukemia

Omer H Jamy, Kendall Diebold, Kimo Bachiashvili, Sravanti Rangaraju, Pankit Vachhani, Kelly N. Godby, Donna Salzman, Ravi Bhatia

Blood (2022) 140 (Supplement 1): 8959–8960.

https://doi.org/10.1182/blood-2022-160346

Published: 2022

Journal Articles

Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers

Blood (2022) 140 (Supplement 1): 7731–7733.

https://doi.org/10.1182/blood-2022-157985

Published: 2022

Journal Articles

Real-World Treatment Experience of Venetoclax in Combination with Hypomethylating Agents in Patients with Newly Diagnosed Acute Myeloid Leukemia: Updated Experience from a Predominately Community Setting in the US

Pankit Vachhani, Esprit Ma, Tao Xu, Melissa Montez, Sarah Worth, Wei-Han Cheng, Michael Werner, Jonathan Abbas, William Donnellan

Blood (2022) 140 (Supplement 1): 683–684.

https://doi.org/10.1182/blood-2022-157509

Published: 2022

Journal Articles

Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative

Blood (2022) 140 (Supplement 1): 11026–11028.

https://doi.org/10.1182/blood-2022-159615

Published: 2022

Journal Articles

INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis: A Phase 1 Study

Justin Watts, Anthony M. Hunter, Alessandra Iurlo, Blanca Xicoy, Francesca Palandri, Brandi Reeves, Alessandro M. Vannucchi, Xuejun Chen, Francis Seguy, Feng Zhou, Fred Zheng, Pankit Vachhani

Blood (2022) 140 (Supplement 1): 9696–9697.

https://doi.org/10.1182/blood-2022-169740

Published: 2022

Journal Articles

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML

Blood (2022) 139 (24): 3546–3557.

https://doi.org/10.1182/blood.2021014520

Published: 2022

Includes: Supplemental data

Journal Articles

Real World Treatment Patterns and Outcomes of Venetoclax (Ven) and Hypomethylating Agents (HMA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States

Pankit Vachhani, Jonathan A. Abbas, Evelyn M. Flahavan, Esprit Ma, Tao Xu, Huan Jin, Melissa Montez, Weize Huang, Anda Gershon, Grace Ku, Brannon Flores, Maika Onishi, Cat N. Bui, William Donnellan

Blood (2021) 138 (Supplement 1): 2290.

https://doi.org/10.1182/blood-2021-147851

Published: 2021

Journal Articles

Comparative Effectiveness of Venetoclax Combinations Vs Other Therapies Among Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from the AML Real World Evidence (ARC) Initiative

Blood (2021) 138 (Supplement 1): 2328.

https://doi.org/10.1182/blood-2021-151285

Published: 2021

Journal Articles

Hypomethylating Agent/Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia

Omer Hassan Jamy, Sarah Worth, Sravanti Rangaraju, Kimo Bachiashvili, Pankit Vachhani, Ravi Bhatia

Blood (2021) 138 (Supplement 1): 2322.

https://doi.org/10.1182/blood-2021-149778

Published: 2021

Journal Articles

Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis

Amanda Przespolewski, Aaron D Goldberg, Chetasi Talati, Salman Fazal, Pankit Vachhani, Srinivasa Reddy R. Sanikommu, Swapna Thota, Julian Waksal, Brian Ball, Christopher Famulare, Maximilian Stahl, Zoe Mckinnell, Jeffrey Baron, Elizabeth A. Griffiths, James E. Thompson, Kendra Sweet, Eunice S. Wang

Blood (2021) 138 (Supplement 1): 1264.

https://doi.org/10.1182/blood-2021-153791

Published: 2021

Journal Articles

Real-World Management of Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax-Based Regimens: Results from the AML Real World Evidence (ARC) Initiative

Blood (2021) 138 (Supplement 1): 1271.

https://doi.org/10.1182/blood-2021-151586

Published: 2021

Journal Articles

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia

Blood (2021) 138 (5): 387–400.

https://doi.org/10.1182/blood.2020008812

Published: 2021

Includes: Supplemental data

Journal Articles

Risk of Mortality and Leukemic Transformation in Primary Myelofibrosis before and after Ruxolitinib Approval

John William Thomas, Mithun Vinod Shah, MD PhD, Pankit Vachhani, MD, Omer Jamy, MD, Ronald S. Go, MD, Gaurav Goyal, MD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-134161

Published: 2020

Journal Articles

Quantification of Humoral Immune Response to Influenza Vaccination in MDS

Pankit Vachhani, MD, Kyle Wiatrowski, Pragya Srivastava, PhD, Lisa King, Jody Manischewitz, Hana Golding, Heather L Bashaw, BA, Ava R. Dimitroff, Amanda Przespolewski, DO, James E. Thompson, MD, Swapna Thota, MD, Eunice S. Wang, MD, Michael J. Nemeth, PhD, Elizabeth A. Griffiths, MD

Blood (2019) 134 (Supplement_1): 4756.

https://doi.org/10.1182/blood-2019-126176

Published: 2019

Journal Articles

Ramp-up Treatment Strategy in Philadelphia Positive Acute Lymphoblastic Leukemia Is Associated with Deep Molecular Remissions and Favorable Outcomes

Nabiel A. Mir, MD, Charles Bodine, MD, Denise Peker, MD, Kimo Bachiashvili, MD, Pankit Vachhani, MD, Luciano J. Costa, MD PhD, Harry P. Erba, MD PhD, Nikolaos Papadantonakis, MD PhD MSc

Blood (2019) 134 (Supplement_1): 5120.

https://doi.org/10.1182/blood-2019-128770

Published: 2019

Journal Articles

Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE ® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Marion Subklewe, MD, Anthony Stein, MD, Roland B. Walter, MD PhD MS, Ravi Bhatia, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, David Ritchie, MD PhD, Veit Bücklein, MD, Pankit Vachhani, MD, Tian Dai, PhD, Antreas Hindoyan, PhD, Suresh Agarwal, PhD, Abraham Anderson, Sophia Khaldoyanidi, MD PhD, Farhad Ravandi, MD

Blood (2019) 134 (Supplement_1): 833.

https://doi.org/10.1182/blood-2019-127977

Published: 2019

Journal Articles

Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission

Blood (2019) 134 (Supplement_1): 48.

https://doi.org/10.1182/blood-2019-125967

Published: 2019

NARROW

Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Impact of Therapy on the Anamnestic Response to Seasonal Influenza Vaccination in Patients with Myeloid Malignancies

Optimal Induction and Consolidation Strategy for Patients with Complex Karyotype and TP53 -Mutated Acute Myeloid Leukemia

Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers

Real-World Treatment Experience of Venetoclax in Combination with Hypomethylating Agents in Patients with Newly Diagnosed Acute Myeloid Leukemia: Updated Experience from a Predominately Community Setting in the US

Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative

INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis: A Phase 1 Study

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML

Real World Treatment Patterns and Outcomes of Venetoclax (Ven) and Hypomethylating Agents (HMA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States

Comparative Effectiveness of Venetoclax Combinations Vs Other Therapies Among Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from the AML Real World Evidence (ARC) Initiative

Hypomethylating Agent/Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia

Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis

Real-World Management of Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax-Based Regimens: Results from the AML Real World Evidence (ARC) Initiative

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia

Risk of Mortality and Leukemic Transformation in Primary Myelofibrosis before and after Ruxolitinib Approval

Quantification of Humoral Immune Response to Influenza Vaccination in MDS

Ramp-up Treatment Strategy in Philadelphia Positive Acute Lymphoblastic Leukemia Is Associated with Deep Molecular Remissions and Favorable Outcomes

Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE ® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only